T-705, A Novel Anti-Influenza Virus Compound - the Safety, Tolerability and Pharmacokinetics in Human  by Kobayashi, O. et al.
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e299
46.020
Th Genes and Dengue Virus Infection
J.C. Chen, M.L. Ng, J.J.H. Chu ∗
Department of Microbiology, Yong Loo Lin School of
Medicine, National University of Singapore, Singapore, Sin-
gapore
Background: Little is currently known about the
immunopathogenesis of dengue virus infection. However,
the complex interaction of host immune responses during
dengue virus infection has important implications on the
clinical outcome of patients. The role of Th genes during
dengue virus infection is poorly deﬁned.
Methods: In this project, we determine which genes are
differentially regulated in dengue type 2 virus-infected cell
lines (HepG2 -hepatocytes, K562 - myelogenous leukaemia
cell line and Jurkat - T cells). We used real-time PCR to
proﬁle the expression of 84 genes related to the three
classes of helper T cells: Th1, Th2 and Th3. This array
includes cytokine and chemokine genes representative of
Th1, Th2 and Th3 cells, transcriptional factors that regulate
the expression of these cytokines as well as genes involved
in the antimicrobial humoral response.
Results: The susceptibilities of the three cell lines to
dengue type 2 virus were evident by detection of viral
antigen and virus growth curve. Majority of the Th genes
that are differentially regulated in all the three cell lines
infected with dengue virus. However, Jurkat and K562 cells
showed more common regulation as compared to HepG2
cells probably because both of them are leukocytes. Among
the differentially regulated genes, TLR6 was signiﬁcantly
regulated in both dengue type 2 virus-infected K562 cells
and Jurkat cells. Semi-quantitative PCR and Western detec-
tion were performed to conﬁrm the up-regulation of TLR6.
High level of IL-6 expression was also detected from K562
cells and Jurkat cells.
Conclusion: K562 and Jurkat cells are permissive to
dengue type 2 virus infection. TLR 6 is up-regulated which in
turn leads to upregulation of IL-6 during dengue virus infec-
tion. This may have implications in the immunopathogenesis
of dengue virus biology.
doi:10.1016/j.ijid.2008.05.801
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Background: The spread of H5N1 virus in humans has
highlighted the threat of worldwide pandemic. T-705 is
a novel antiviral agent for treatment of inﬂuenza infec-
tion containing avian ﬂu. The compound has been found
to possess a potent and selective inhibitory activity against
broad spectrum inﬂuenza viruses including H5N1 strains
both in vitro and in vivo. T-705 is converted to the ribo-
syl phosphates by host cellular enzymes, and the ribosyl
triphosphate inhibits viral RNA polymerase selectively. The
antiviral mechanism of T-705 differs from currently pre-
scribed drugs involving the neuraminidase inhibitors and the
viral M2 protein ion channel inhibitors. Thus, T-705 may be
valuable for patients suffering from uncomplicated seasonal
inﬂuenza as well as complicated seasonal and/or avian ﬂu
infection.
Method: Phase 1 studies of T-705a, a code name for
oral formulations of T-705, have been conducted in healthy
volunteers in Japan. The single dose study was designed
as a randomized, double-blind, placebo-controlled, dose-
ascending trial in 48 men. The multiple dose for 7 days study
was designed as a randomized, double-blinded, placebo-
controlled, dose-ascending trial in 24 men.
Result: In the single dose of 30 to 1600mg, T-705 was
characterised by rapid absorption and elimination into urine
as T-705M1, the major metabolite and hydroxide of T-
705. Cmax increased approximately proportionally to dose.
AUCinf, however, increased more than proportionally to
dose. In the ﬁrst group of the multiple dose study, the
plasma T-705 concentration increased progressively due to
inhibition of metabolic enzyme. Plasma T-705 concentra-
tion was controlled up to 1200mg/day by modifying the
dosage and administration. No serious adverse events were
reported.
Conclusion: Single and multiple oral dose of T-705 were
well-tolerated. These results indicate deserving to progress
next studies for patients with inﬂuenza infection.
doi:10.1016/j.ijid.2008.05.802
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Background: Clinical spectrum of EV71 infection ranges
from mild hand-foot-mouth disease (HFMD) to severe
cases with central nervous system and cardiopulmonary
involvements. In 1998, Taiwan suffered a nation-wide EV71
epidemic with 405 reported severe cases and 78 fatal cases.
Since then, EV71 has been endemic in Taiwan and develop-
ment of EV71 vaccines has become a national priority. This
cohort study was designed to understand decline of maternal
EV71 neutralizing antibody titers and age-speciﬁc incidence
rates of EV71 infection in Taiwan, which will be crucial for
designing efﬁcacy trials of EV71 vaccines.
Methods: This study is a prospective longitudinal cohort
study and was approved by the Institutional Review Boards
in CGMH and NHRI. Pregnant women having prenatal exams
were invited to participate. Sera were collected from par-
ticipating mother/baby for measuring EV71 neutralizing
